IL325801A - Therapy for alpha-1 antitrypsin deficiency - Google Patents

Therapy for alpha-1 antitrypsin deficiency

Info

Publication number
IL325801A
IL325801A IL325801A IL32580126A IL325801A IL 325801 A IL325801 A IL 325801A IL 325801 A IL325801 A IL 325801A IL 32580126 A IL32580126 A IL 32580126A IL 325801 A IL325801 A IL 325801A
Authority
IL
Israel
Prior art keywords
mirna
aat
targets
seq
guide
Prior art date
Application number
IL325801A
Other languages
English (en)
Hebrew (he)
Original Assignee
Precigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc filed Critical Precigen Inc
Publication of IL325801A publication Critical patent/IL325801A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL325801A 2023-07-10 2024-07-10 Therapy for alpha-1 antitrypsin deficiency IL325801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363512773P 2023-07-10 2023-07-10
PCT/US2024/037285 WO2025014986A2 (en) 2023-07-10 2024-07-10 Therapy for alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
IL325801A true IL325801A (en) 2026-03-01

Family

ID=94216330

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325801A IL325801A (en) 2023-07-10 2024-07-10 Therapy for alpha-1 antitrypsin deficiency

Country Status (8)

Country Link
EP (1) EP4743578A2 (de)
JP (1) JP2026524013A (de)
KR (1) KR20260042173A (de)
CN (1) CN121909290A (de)
AU (1) AU2024288666A1 (de)
IL (1) IL325801A (de)
MX (1) MX2026000042A (de)
WO (1) WO2025014986A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025155773A1 (en) * 2024-01-19 2025-07-24 Gene Company (Pty)Ltd. Telomerase upregulating polynucleotide and method of use and treatment thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628327A1 (de) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CN114072500B (zh) * 2019-08-02 2024-05-10 香港科技大学 控制microRNA表达的方法
AU2022205683A1 (en) * 2021-01-11 2023-07-06 Precigen, Inc. Chimeric receptor therapy

Also Published As

Publication number Publication date
EP4743578A2 (de) 2026-05-20
CN121909290A (zh) 2026-04-21
WO2025014986A2 (en) 2025-01-16
JP2026524013A (ja) 2026-07-16
WO2025014986A3 (en) 2025-03-20
KR20260042173A (ko) 2026-03-30
AU2024288666A1 (en) 2026-01-22
MX2026000042A (es) 2026-02-03

Similar Documents

Publication Publication Date Title
EP4362933A4 (de) Komplementhemmung
HUE064089T2 (hu) Alvelesztat neutrofil elasztáz inhibitort alkalmazó módszerek alfa-1-antitripszin hiány által közvetített légzõszervi megbetegedés kezelésére
SG11202103735TA (en) Compositions and methods for treating alpha-1 antitrypsin deficiencey
IL318884A (en) Alpha-1 antitrypsin modulators
AU2024288666A1 (en) Therapy for alpha-1 antitrypsin deficiency
IL325521A (en) Budeodrone for the treatment of heart failure
GB202212144D0 (en) Cells for therapy
CA3297720A1 (en) Therapy for alpha-1 antitrypsin deficiency
IL312033A (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
GB202400426D0 (en) Controller
CA219515S (en) Lateral left access fitting
HK40083723A (en) Methods of treatment for alpha-1 antitrypsin deficiency
HK40115697A (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
HK40066512A (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
CA3293811A1 (en) Methods and compositions for treating alpha-1 antitrypsin deficiency
HK40069924A (en) Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
CA230440S (en) Controller
CA3305693A1 (en) Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders
HK40109230A (en) Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
HK40109562A (en) Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
CA231442S (en) Controller
CA229583S (en) Controller
CN309470659S (en) Bidet controller
CN309526316S (en) Bidet controller
GB202303126D0 (en) Controller